The stem cell treatment hopeful plunged 41 per cent at the open after revealing its COVID research was unlikely to meet its goals.
source https://www.smh.com.au/business/companies/mesoblast-shares-savaged-on-poor-covid-trial-results-20201218-p56onp.html?ref=rss&utm_medium=rss&utm_source=rss_feed
source https://www.smh.com.au/business/companies/mesoblast-shares-savaged-on-poor-covid-trial-results-20201218-p56onp.html?ref=rss&utm_medium=rss&utm_source=rss_feed
Tags:
Sydney Morning